NYSE:DNA

Ginkgo Bioworks (DNA) Stock Forecast, Price & News

$1.77

+0.02 (+1.14%)

(As of 09/22/2023 08:51 PM ET)

Compare

Today's Range: $1.74
▼
$1.81
50-Day Range: $1.61
▼
$2.54
52-Week Range: $1.12
▼
$3.52

Volume: 14.90 million shs
Average Volume: 21.22 million shs
Market Capitalization: $3.71 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.75

Ginkgo Bioworks MarketRank™ Forecast

Analyst Rating: Hold
2.20 Rating Score
Upside/Downside: 111.9% Upside
$3.75 Price Target
Short Interest: Bearish
16.44% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.41
Based on 9 Articles This Week
Insider Trading: Selling Shares
$2.69 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.35) to ($0.28) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

723rd out of 962 stocks

Biological Products, Except Diagnostic Industry

115th out of 155 stocks

3.1

Analyst's Opinion

Consensus Rating
Ginkgo Bioworks has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $3.75, Ginkgo Bioworks has a forecasted upside of 111.9% from its current price of $1.77.
Amount of Analyst Coverage
Ginkgo Bioworks has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
16.44% of the float of Ginkgo Bioworks has been sold short.
Short Interest Ratio / Days to Cover
Ginkgo Bioworks has a short interest ratio ("days to cover") of 9.
Change versus previous month
Short interest in Ginkgo Bioworks has recently increased by 0.41%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Ginkgo Bioworks does not currently pay a dividend.
Dividend Growth
Ginkgo Bioworks does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DNA.

2.5

News and Social Media Coverage

News Sentiment
Ginkgo Bioworks has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Ginkgo Bioworks this week, compared to 5 articles on an average week.
Search Interest
Only 54 people have searched for DNA on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
MarketBeat Follows
45 people have added Ginkgo Bioworks to their MarketBeat watchlist in the last 30 days. This is an increase of 73% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ginkgo Bioworks insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,687,031.00 in company stock.
Percentage Held by Insiders
15.05% of the stock of Ginkgo Bioworks is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
56.84% of the stock of Ginkgo Bioworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Ginkgo Bioworks are expected to grow in the coming year, from ($0.35) to ($0.28) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ginkgo Bioworks is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ginkgo Bioworks is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ginkgo Bioworks has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ginkgo Bioworks (NYSE:DNA) Stock

Ginkgo Bioworks Holdings Inc. is a biotech company attempting to revolutionize the biotechnology industry by engineering completely new organisms. Founded in 2008 by Jason Kelly, Austin Che, Thomas Knight Jr. and Bartholomew Canton, the company operates a market-agnostic platform utilizing the latest technologies to pioneer the development of more sustainable biotechnology and bioengineering applications.

Ginkgo Bioworks Holdings Inc. develops multiple platforms for food production, agriculture, industrial and pharmaceuticals. These platforms enable bioengineering applications across diverse markets, and the company customizes organisms for customers ranging from large companies to smaller startups. The company also creates proprietary software, algorithms and automation to engineer "customizable organisms" for their customers and the development of new products for the industrial and consumer markets.

The company has earned multiple awards for its innovative technology in biologics, including the National Science Foundation's Innovation Corps Award, the National Academy of Engineering's Grand Challenges Award and the World Economic Forum's Technology Pioneers Award.

Ginkgo Bioworks Holdings Inc. has partnered with prestigious organizations, including the Broad Institute of MIT, Harvard, Genomics England, the National Institutes of Health and the National Science Foundation's Innovation Corps to further their mission of making biotechnology more accessible to smaller and medium-sized organizations.

Ginkgo Bioworks Holdings Inc. strives to revolutionize the biotech industry, attempting to pioneer the development of an ecosystem that will provide more sustainable and accessible biotechnology systems. With the help of innovative technology and strategic partnerships with prestigious organizations, Ginkgo Bioworks Holdings Inc. is well on its way to achieving this goal and making biotechnology more accessible to smaller and medium-sized organizations.

Ginkgo Bioworks Holdings Inc. has a market cap of approximately $2.97 billion, down from $3.98 in 2022. However, the company has seen rapid growth since 2020, increasing revenues from $3.8 million in 2017 to $313.8 million in 2022.

DNA Price History

30 days | 90 days | 365 days | Advanced Chart

DNA Stock News Headlines

September 21, 2023 | americanbankingnews.com

Financial Analysis: Ginkgo Bioworks (NYSE:DNA) versus Sorrento Therapeutics (NASDAQ:SRNE)

September 20, 2023 | msn.com

Cathie Wood sinks hundreds of thousands into a super-cheap tech stock (again)

September 25, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

September 19, 2023 | americanbankingnews.com

Ginkgo Bioworks (NYSE:DNA) Trading Down 4.9% on Insider Selling

September 18, 2023 | msn.com

Ginkgo Bioworks, Factorial to develop new single-cell library prep kit enzyme

September 18, 2023 | markets.businessinsider.com

Ginkgo Bioworks, Factorial Join To Develop Enzyme For Single-Cell Library Prep Technology

September 18, 2023 | americanbankingnews.com

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Insider Sells $76,806.00 in Stock

September 17, 2023 | americanbankingnews.com

Ginkgo Bioworks (NYSE:DNA) Shares Gap Down on Insider Selling

September 25, 2023 | Behind the Markets (Ad)

3 Words and a 3,000% Return

In October 2013, a scientist wrote 3 words on a piece of paper. They were simple words. A fiveyear-old could say them. But these three words could deliver you a 3,000% return in 2023 >>>

September 6, 2023 | finance.yahoo.com

Ginkgo Bioworks Announces Participation in Morgan Stanley 21st Annual Global Healthcare Conference

September 3, 2023 | msn.com

Why Ginkgo Bioworks Stock Was a 34% Winner This Week

September 1, 2023 | msn.com

Ginkgo Bioworks CEO: Our AI model will learn to speak DNA just like ChatGPT learned English

August 31, 2023 | msn.com

Exacta Bioscience to use Ginkgo Bioworks agritech for product enhancement

August 31, 2023 | finance.yahoo.com

Exacta Bioscience and Ginkgo Bioworks Announce Partnership to Optimize Exacta's Crop Protection Product

August 30, 2023 | benzinga.com

What's Going On With Ginkgo Bioworks Stock?

August 30, 2023 | seekingalpha.com

Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)

August 30, 2023 | msn.com

Why Did This Cathie Wood Stock Soar 24% on Tuesday?

August 30, 2023 | finance.yahoo.com

Ginkgo Bioworks to Host Investor Day on October 3, 2023

August 30, 2023 | markets.businessinsider.com

BTIG Keeps Their Buy Rating on Ginkgo Bioworks Holdings (DNA)

August 29, 2023 | markets.businessinsider.com

Berenberg Bank Remains a Buy on Ginkgo Bioworks Holdings (DNA)

August 29, 2023 | benzinga.com

Why Ginkgo Bioworks Stock Is Climbing Tuesday

August 29, 2023 | finance.yahoo.com

Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and Biosecurity

August 21, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Ginkgo Bioworks Holdings (DNA), Sagimet Biosciences, Inc. Class A (SGMT)

August 18, 2023 | seekingalpha.com

Ginkgo Bioworks: Lack Of Progress Is A Concern

August 10, 2023 | seekingalpha.com

Ginkgo Bioworks: Major Revenue Trouble (Ratings Downgrade)

August 10, 2023 | markets.businessinsider.com

Bank of America Securities Remains a Sell on Ginkgo Bioworks Holdings (DNA)

August 9, 2023 | finance.yahoo.com

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q2 Loss, Tops Revenue Estimates

See More Headlines

Receive DNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter.

DNA Company Calendar

Last Earnings: 8/09/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:DNA
CUSIP: N/A
CIK: 1830214
Web: www.eagleequityptnrs.com
Phone: 877-442-5362
Fax: N/A
Employees: 1,292
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.75
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $1.25
Forecasted Upside/Downside: +111.9%
Consensus Rating: Hold
Rating Score (0-4): 2.20
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.71)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-2,104,930,000.00
Net Margins: -375.48%
Pretax Margin: -379.24%
Return on Equity: -66.58%
Return on Assets: -45.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.49
Quick Ratio: 7.49

Sales & Book Value

Annual Sales: $477.71 million
Price / Sales: 7.78
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.89 per share
Price / Book: 1.99

Miscellaneous

Outstanding Shares: 2,098,850,000
Free Float: 1,782,976,000
Market Cap: $3.71 billion
Optionable: Optionable
Beta: 1.17

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Jason Kelly (Age 42)
Founder, CEO & Director
Comp: $262.5k

Dr. Reshma P. Shetty (Age 42)
Founder, Pres, COO & Director
Comp: $262.5k

Mr. Mark E. Dmytruk (Age 52)
Chief Financial Officer
Comp: $465.25k

Mr. Thomas Knight Jr.
Founder

Mr. Austin Che
Founder, Head of Strategy & Treasurer

Mr. Bartholomew Canton
Founder, CTO & Sec.

Mr. Steven P. Coen CPA
Chief Accounting Officer

Karen Tepichin
Gen. Counsel & Sec.

Ms. Anna Marie Wagner
Sr. VP of Corp. Devel.

Ms. Samantha Sutton
Head of People

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DNA Stock - Frequently Asked Questions

Should I buy or sell Ginkgo Bioworks stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DNA, but not buy additional shares or sell existing shares.
View DNA analyst ratings or view top-rated stocks.
What is Ginkgo Bioworks' stock price forecast for 2023?: 5 equities research analysts have issued 1 year target prices for Ginkgo Bioworks' stock. Their DNA share price forecasts range from $1.25 to $6.00. On average, they predict the company's stock price to reach $3.75 in the next twelve months. This suggests a possible upside of 111.9% from the stock's current price.
View analysts price targets for DNA or view top-rated stocks among Wall Street analysts.
How have DNA shares performed in 2023?: Ginkgo Bioworks' stock was trading at $1.69 at the beginning of the year. Since then, DNA stock has increased by 4.7% and is now trading at $1.77.
View the best growth stocks for 2023 here.
When is Ginkgo Bioworks' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our DNA earnings forecast.
How were Ginkgo Bioworks' earnings last quarter?: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) issued its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.09) EPS for the quarter, meeting the consensus estimate of ($0.09). The firm had revenue of $80.57 million for the quarter, compared to the consensus estimate of $70.41 million. Ginkgo Bioworks had a negative net margin of 375.48% and a negative trailing twelve-month return on equity of 66.58%.
What ETFs hold Ginkgo Bioworks' stock?: ETFs with the largest weight of Ginkgo Bioworks (NYSE:DNA) stock in their portfolio include VegTech Plant-based Innovation & Climate ETF (EATV), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), Direxion Moonshot Innovators ETF (MOON), WisdomTree BioRevolution Fund (WDNA), IQ U.S. Mid Cap R&D Leaders ETF (MRND) and Range Cancer Therapeutics ETF (CNCR).

What guidance has Ginkgo Bioworks issued on next quarter's earnings?: Ginkgo Bioworks issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $245.00 million-$260.00 million, compared to the consensus revenue estimate of $292.83 million.
What is Ginkgo Bioworks' stock symbol?: Ginkgo Bioworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "DNA."
Who are Ginkgo Bioworks' major shareholders?: Ginkgo Bioworks' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (11.56%), ARK Investment Management LLC (8.14%), BlackRock Inc. (3.27%), Sumitomo Mitsui Trust Holdings Inc. (2.44%), State Street Corp (0.99%) and Geode Capital Management LLC (0.83%). Insiders that own company stock include Barry Canton, Christian O Henry, Jason R Kelly, Marie E Fallon, Marijn E Dekkers, Mark E Dmytruk, Reshma P Shetty and Shyam Sankar.
View institutional ownership trends.
How do I buy shares of Ginkgo Bioworks?: Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ginkgo Bioworks' stock price today?: One share of DNA stock can currently be purchased for approximately $1.77.
How much money does Ginkgo Bioworks make?: Ginkgo Bioworks (NYSE:DNA) has a market capitalization of $3.71 billion and generates $477.71 million in revenue each year. The company earns $-2,104,930,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis.
How many employees does Ginkgo Bioworks have?: The company employs 1,292 workers across the globe.
How can I contact Ginkgo Bioworks?: Ginkgo Bioworks' mailing address is 955 Fifth Avenue, New York NY, 10075. The official website for the company is www.eagleequityptnrs.com. The company can be reached via phone at 877-442-5362 or via email at investors@ginkgobioworks.com.

This page (NYSE:DNA) was last updated on 9/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial